Yoshihiro Kamada, Masafumi Ono, Hideyuki Hyogo, Hideki Fujii, Yoshio Sumida, Kojiroh Mori, Saiyu Tanaka, Makoto Yamada, Maaya Akita, Kayo Mizutani, Hironobu Fujii, Akiko Yamamoto, Shinji Takamatsu, Yuichi Yoshida, Yoshito Itoh, Norifumi Kawada, Kazuaki Chayama, Toshiji Saibara, Tetsuo Takehara, Eiji Miyoshi – 21 July 2015 – Nonalcoholic fatty liver disease (NAFLD) is a growing medical problem; thus, discriminating nonalcoholic steatohepatitis (NASH) from NAFLD is of great clinical significance.

Siddharth Sood, Craig Haifer, Lijia Yu, Julie Pavlovic, Paul J. Gow, Robert M. Jones, Kumar Visvanathan, Peter W. Angus, Adam G. Testro – 20 July 2015 – Cytomegalovirus (CMV) can reactivate following liver transplantation. Management of patients currently considered low risk based on pretransplant serology remains contentious, with universal prophylaxis and preemptive strategies suffering from significant deficiencies.

Mamatha Bhat, Peter Ghali, Kathleen C. Rollet‐Kurhajec, Aparna Bhat, Philip Wong, Marc Deschenes, Giada Sebastiani – 20 July 2015 – Noninvasive serum fibrosis biomarkers predict clinical outcomes in pretransplant patients with chronic liver disease. We investigated the role of serum fibrosis biomarkers and of changes in biomarkers in predicting death and graft loss after liver transplantation (LT).

James Fung, Regina Lo, See‐Ching Chan, Kenneth Chok, Tiffany Wong, William Sharr, Tan‐To Cheung, Albert C. Y. Chan, Wing‐Chiu Dai, Sui‐Ling Sin, Irene Ng, Ching‐Lung Lai, Man‐Fung Yuen, Chung‐Mau Lo – 20 July 2015 – The outcomes of hepatitis B virus (HBV)–related hepatitis after liver transplantation (LT) without hepatitis B immune globulin (HBIG) is not well documented. This study aims to determine the outcomes of chronic hepatitis B (CHB) patients using an HBIG‐free regimen.

Siddharth Singh, Rohan Khera, Alina M. Allen, M. Hassan Murad, Rohit Loomba – 18 July 2015 – We performed a Bayesian network meta‐analysis combining direct and indirect treatment comparisons to assess the comparative effectiveness of pharmacological agents for the treatment of nonalcoholic steatohepatitis (NASH). Through systematic literature review, we identified nine randomized, controlled trials (RCTs) including 964 patients with biopsy‐proven NASH, comparing vitamin E, thiazolidinediones (TZDs), pentoxifylline, or obeticholic acid to one another or placebo.

Siddharth Singh, Rohan Khera, Alina M. Allen, M. Hassan Murad, Rohit Loomba – 18 July 2015 – We performed a Bayesian network meta‐analysis combining direct and indirect treatment comparisons to assess the comparative effectiveness of pharmacological agents for the treatment of nonalcoholic steatohepatitis (NASH). Through systematic literature review, we identified nine randomized, controlled trials (RCTs) including 964 patients with biopsy‐proven NASH, comparing vitamin E, thiazolidinediones (TZDs), pentoxifylline, or obeticholic acid to one another or placebo.

16 July 2015

Alessandro Vitale, Fabio Farinati, Patrizia Burra, Franco Trevisani, Edoardo G.

Muhammed Yuksel, Yipeng Wang, Ningwen Tai, Jian Peng, Junhua Guo, Kathie Beland, Pascal Lapierre, Chella David, Fernando Alvarez, Isabelle Colle, Huiping Yan, Giorgina Mieli‐Vergani, Diego Vergani, Yun Ma, Li Wen – 16 July 2015 – Autoimmune hepatitis (AIH) in humans is a severe inflammatory liver disease characterized by interface hepatitis, the presence of circulating autoantibodies, and hyper‐gammaglobulinemia. There are two types of AIH, type 1 (AIH‐1) and type 2 (AIH‐2), characterized by distinct autoimmune serology.

Huey‐Huey Chua, Daw‐Jen Tsuei, Po‐Huang Lee, Yung‐Ming Jeng, Jean Lu, Jia‐Feng Wu, De‐Shiuan Su, Ya‐Hui Chen, Chin‐Sung Chien, Pei‐Chi Kao, Chien‐Nan Lee, Rey‐Heng Hu, Yen‐Hsuan Ni, Mei‐Hwei Chang – 16 July 2015 – Male predominance of hepatocellular carcinoma (HCC) occurs particularly among young children aged 6‐9 years, indicative of a possible role of the Y chromosome–encoded oncogene in addition to an androgenic effect.